Pathway Analysis for Design of Promiscuous Drugs and Selective Drug Mixtures

Abstract

The decrease in the drug approval rate by the FDA and the recent failure of some blockbuster drugs has prompted a re-examination of the focus of the pharmaceutical industry on increasing drug selectivity. As a result, it has been proposed that the most efficient cure is in developing promiscuous drugs and selective drug mixtures. Rational design of drug mixtures has been nearly impossible due to the lack of information about in vivo cell regulation, mechanisms of pathway activation, and interactions between different pathways in vivo. We review the current state of the art for rational design of combination therapy and argue that the current industry-wide development of the infrastructure for pathway analysis provides unprecedented opportunity for the rational design of multicomponent and multifunctional drugs. We propose several ways how to use pathway analysis to rationally combine known drugs for either synergizing their efficacy or suppressing individual side effects.

Mu/kappa opioid interactions in rhesus monkeys: Implications for analgesia and abuse liability.

“…This variety of potential mechanisms underscores both the importance of examining drug interactions across a range of endpoints and the risk of generalizing drug interactions from any one endpoint to any other endpoint. However, this complexity also provides the basis for an opportunity to develop drug mixtures or mixed-actions drugs that produce enhanced desirable effects and/or reduced undesirable effects relative to highly selective drugs administered alone (Sivachenko, Kalinin, & Yuryev, 2006). …”

Multifunctional Receptor-Directed Drugs for Disorders of the Central Nervous System

“…Irrespective of which of these approaches is most successful in the coming years, it is likely that the Alzheimer's or Parkinson's patient of the future will require multiple treatment approaches, both palliative and disease-modifying. Sivachenko and colleagues 5 have argued that the recent downward trend in Food and Drug Administration approval rates is attributed to the "magic bullet" approach. They contend that pathway analysis allows for multiple target development that is more relevant to CNS disorders, which are complex and multigenetic in origin.…”

Profiling the Nanoparticles Associated Protein-protein Interactions

“…Construction By use of the graph-based representation, it is possible for us to (i) analyze the literate about nanoparticles associated genes, (ii) analyze the gene expression patterns in different model organisms, and (iii) predict nanoparticles response based on gene expression profiles [1][2][3]12].…”

“…Bioinformatics systems biology is a cutting-edge biological field that focuses on high through-put experimental data mining, database organization, and the systematic study of complex interactions in cellular systems [2,3]. Furthermore, the regulatory network or pathway modeling of cancer development processes becomes a major issue for bioinformatics systems biological studies in present day.…”

“…Furthermore, the regulatory network or pathway modeling of cancer development processes becomes a major issue for bioinformatics systems biological studies in present day. Based on these bioinformatics studies, further labexperiments can be conducted to clarify the pharmacologic potential and develop effective cancer therapies [3,4].…”